A. A. Kogan

Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia

S. Baylin, F. Rassool, M. Baer, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency

S. Baylin, F. Rassool, L. Xia, 2020, Proceedings of the National Academy of Sciences.

Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment

F. Rassool, M. Baer, R. Lapidus, 2019, Advances in cancer research.

DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation

S. Baylin, D. Fontaine, F. Rassool, 2019, Proceedings of the National Academy of Sciences.

Abstract 6301: DNA methyltransferase inhibitors increase ERV reactivation and STING-dependent interferon/inflammasome signaling in TP53 mutant AML

S. Baylin, F. Rassool, M. Baer, 2022, Cancer Research.

[Radioisotope study of uterine tubal patency].

S. Alimov, A. A. Kogan, V. Ginzburg, 1973, Akusherstvo i ginekologiia.

Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed/refractory acute myeloid leukemia.

S. Baylin, S. Bentzen, F. Rassool, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

DNA Demethylating Agents Generate a Brcaness Effect in Multiple Sporadic Tumor Types: Prediction for Sensitivity to PARP Inhibitors in AML

S. Baylin, C. Civin, S. Bentzen, 2017 .